An important strategy to improve the efficacy of ACT is starting with a pool of human CD8+ T cells enriched with anti-tumor activity, rather than the whole CD8+ population where tumor-reactive cells only occupy a small fraction. The gene discussed is CD8A; the disease is neoplasm.